Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]
Discontinued
Reference number: GID-TA10494
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal (STA) of idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia.
Following a recent update from the company, NICE has decided to suspend this appraisal on its work programme.
As the appraisal has been referred, NICE will continue to monitor any developments and will provide a further update in due course.